n-butyl 2,4-dihydroxy-3,6-dimethylbenzoate | 75950-52-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: n-butyl 2,4-dihydroxy-3,6-dimethylbenzoate
• 英文别名: Butyl 2,4-dihydroxy-3,6-dimethylbenzoate
• CAS: 75950-52-6
• 化学式: C₁₃H₁₈O₄
• 分子量: 238.284
• InChiKey: KIZRMFPXOUIZHE-UHFFFAOYSA-N

物化性质

• 熔点：
  123 °C
• 沸点：
  394.2±22.0 °C(Predicted)
• 密度：
  1.155±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  n-butyl 2,4-dihydroxy-3,6-dimethylbenzoate 生成 3-formyl-4,6-dihydroxy-2,5-dimethyl-benzoic acid butyl ester
  参考文献：
  名称：

  Fujikawa; Nakamura, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1942, vol. 62, p. 508; dtsch. Ref. S. 158

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 硫酸 作用下， 生成 n-butyl 2,4-dihydroxy-3,6-dimethylbenzoate
  参考文献：
  名称：

  Fujikawa; Shimamura; Tarui, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1941, vol. 61, p. 191,194; dtsch. Ref. S. 81

  摘要：

  DOI：

文献信息

• Activity-Guided Isolation of an Antiandrogenic Compound of<i>Pygeum africanum</i>
  作者：Sonja Schleich、Maria Papaioannou、Aria Baniahmad、Rudolf Matusch

  DOI：10.1055/s-2006-941472

  日期：2006.4

  Inactivation of the androgen receptor (AR) through androgen ablation and treatment with antiandrogens is a major goal in the therapy for prostate hyperplasia and prostate cancer. Bioactivity-directed fractionation of a selective dichloromethane extract from the stem bark of Pygeum africanum led to the isolation of the antiandrogenic compound atraric acid. Its activity was examined by an androgen receptor responsive reporter gene assay. For lead structure optimization we transformed the natural occurring compound atraric acid into its ethyl, n-propyl and n-butyl esters and their antiandrogenic activities were examined as well. In addition, benzoic acid was isolated. The structures of all compounds were determined and characterized by means of 1H- and 13C-NMR, HR-EI-mass, IR and UV spectroscopy.

  通过雄激素剥夺和抗雄激素药物治疗来灭活雄激素受体(AR)是治疗前列腺增生和前列腺癌的一个主要目标。从非洲臀果木的树皮中选择性地提取二氯甲烷，再通过生物活性引导的分离方法，得到了一种具有抗雄激素作用的化合物——刺囊酸。其活性是通过雄激素受体应答的报告基因检测方法来检测的。为了进一步优化其结构，我们将其自然界中存在的刺囊酸转化为乙酯、正丙酯和正丁酯，并检测它们的抗雄激素活性。此外，还分离出了苯甲酸。所有化合物的结构都通过1H-NMR、13C-NMR、HR-EI质谱、IR和UV光谱进行了鉴定和表征。
• Fujikawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1940, vol. 60, p. 473,477; dtsch. Ref. S. 177
  作者：Fujikawa

  DOI：——

  日期：——
• Depsides as non-redox inhibitors of leukotriene B4 biosynthesis and HaCaT cell growth. 1. Novel analogues of barbatic and diffractaic acid
  作者：Sunil Kumar KC、Klaus Müller

  DOI：10.1016/s0223-5234(99)00132-4

  日期：1999.12

  A series of barbatic and diffractaic acid analogues has been synthesized and evaluated as inhibitors of leukotriene B-4 (LTB4) biosynthesis and as antiproliferative agents. The 4-O-demethyl barbatic and diffractaic acid derivatives were among the most active compounds in both assays. In particular, ethyl 4-O-demethylbarbatate was the most potent LTB4 biosynthesis inhibitor of this series, with an IC50 value in the submicromolar range. Because the compounds did not show appreciable reactivity against a stable free radical, 2,2-diphenyl-1-picrylhydrazyl, and did not produce appreciable amounts of deoxyribose degradation as a measure of their potency to generate hydroxyl radicals, a simple redox effect could not explain their biological activity. Also, there was no nonspecific cytotoxicity as documented by the activity of lactate dehydrogenase released from the cytoplasm of keratinocytes, which was in the control range. (C) 1999 Editions scientifiques et medicales Elsevier SAS.
• Barrett, Anthony G. M.; Morris, Timothy M.; Barton, Derek H. R., Journal of the Chemical Society. Perkin transactions I, 1980, p. 2272 - 2277
  作者：Barrett, Anthony G. M.、Morris, Timothy M.、Barton, Derek H. R.

  DOI：——

  日期：——
• ISOLIERUNG VON ATRARSÄURE, SYNTHESE VON ATRARSÄURE-DERIVATEN SOWIE VERWENDUNG DER ATRARSÄURE UND IHRER DERIVATE ZUR BEHANDLUNG DES PROSTATAKARZINOMS.
  申请人：LTS LOHMANN Therapie-Systeme AG

  公开号：EP1850857B1

  公开（公告）日：2013-05-22